Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: Preliminary results

Journal of Endocrinological Investigation

Volumn 32, Issue 7, 2009, Pages 590-596

  Bonaccorsi, L ^a   Nesi, G ^a   Nuti, F ^a   Paglierani, M ^a   Krausz, C ^a   Masieri, L ^a   Serni, S ^a   Proietti Pannunzi, L ^b   Fang, Y ^c   Jhanwar, S C ^c   Orlando, C ^a   Carini, M ^a   Forti, G ^a   Baldi, E ^a   Luzzatto, L ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gene fusion; Prostate cancer; PSA recurrence; TMPRSS2:ERG

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; RNA; TRANSCRIPTION FACTOR ERG;

AGED; ANDROGEN ABLATION; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TMPRSS2:ERG FUSION GENE;

ABLATION TECHNIQUES; AGED; ANDROGEN ANTAGONISTS; ANIMALS; GENE FUSION; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; TREATMENT OUTCOME;

EID: 70949083943     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03346514     Document Type: Article

References (32)

1. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 2007, 110: 2119-2152
2. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310: 644-648
3. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006, 66: 3396-3400
4. Petrovics G, Zhang W, Makarem M, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005, 24: 3847-3852
5. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448: 595-599 (Pubitemid 47206938)
6. Mehra R, Tomlins S, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007, 20: 538-544 (Pubitemid 46631996)
7. Lapointe J, Kim YH, Miller MA, et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 2007, 20: 467-473 (Pubitemid 46482370)
8. Nam RK, Sugar L, Wang Z, et al. Expression of TMPRSS2:ERG gene fusion in prostate cacner cells is an important prognostic factor in cancer progression. Cancer Biol Ther 2007, 6: 40-45 (Pubitemid 46294173)
9. Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen YT. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007, 20: 921-928 (Pubitemid 47267823)
10. Winnes M, Lissbrant E, Damber JE, Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 2007, 17: 1033-1036
11. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TLJ, Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008, 14: 3395-3400
12. Bova GS, Fox WM, Epstein JI. Methods of radical prostatectomy specimen processing: a novel technique for harvesting fresh prostate cancer tissue and review of processing techniques. Mod Pathol 1993, 6: 201-207
13. Sobin LH, International Union Against Cancer. TNM Classification of malignant tumors. New York: Wiley-Liss 2002, 84-87
14. Bonaccorsi L., Carloni V., Muratori M., et al. Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology 2000, 141: 3172-3182 (Pubitemid 32269005)
15. Korenchuk S, Lehr JE, MClean L, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001, 15: 163-168 (Pubitemid 32328191)
16. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3: RESEARCH0034.
17. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006, 4: 717-719
18. Clark J, Attard G, Jhavar S, et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 2008, 27: 1993-2003.
19. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006, 66: 8347-8351
20. Alipov V, Nakayama T, Ito M, et al. Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology 2005, 46: 202-208 (Pubitemid 40293019)
21. Nakayama T, Ito M, Ohtsuru A, Naito S, Sekine I. Expression of the ets-1 proto-oncogene in human colorectal carcinoma. Mod Pathol 2001, 14: 415-422 (Pubitemid 32448739)
22. Nakayama T, Yoshizaki A, Naito S, et al. Expression of Ets-1 proto-oncoprotein in gastrointestinal stromal tumors, leiomyomas and schwannomas. World J Gastroenterol 2006, 12: 1743-1746
23. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006, 66: 8337-8341 (Pubitemid 44449140)
24. Cerveira N, Ribeiro F, Peixoto A, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006, 8: 826-832 (Pubitemid 44564838)
25. Hermens KG, van Marion R, van Dekken H, Jenster G, vanWeerden WM, Trapman J. TMPRSS:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 2006, 66: 10658-10663
26. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007, 26: 2667-2673
27. Porter CR, Gallina A, Kodama K. Prostate cancer-specific survival in men treated with hormonal therapy after failure of radical prostatectomy. Eur Urol 2006, 52: 446-452 (Pubitemid 46963429)
28. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007, 23: 4596-4599
29. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008, 27: 253-263
30. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neoadjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006, 4: CD006019.
31. Shen MM, Abate-Shen C. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res 2007, 67: 6535-6538
32. Banach-Petrosky W, Jessen WJ, Ouyang X, et al. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1 Pten mutant mice. Cancer Res 2007, 67: 9089-9096 (Pubitemid 47535894)